Ligand Pharmaceuticals Incorporated - Asset Resilience Ratio
Ligand Pharmaceuticals Incorporated (LGND) has an Asset Resilience Ratio of 16.06% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LGND net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Ligand Pharmaceuticals Incorporated's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see LGND total asset value.
Liquid Assets Composition Over Time
This chart breaks down Ligand Pharmaceuticals Incorporated's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Ligand Pharmaceuticals Incorporated long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $351.06 Million | 16.06% |
| Total Liquid Assets | $351.06 Million | 16.06% |
Asset Resilience Insights
- Good Liquidity Position: Ligand Pharmaceuticals Incorporated maintains a healthy 16.06% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Ligand Pharmaceuticals Incorporated Industry Peers by Asset Resilience Ratio
Compare Ligand Pharmaceuticals Incorporated's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Ligand Pharmaceuticals Incorporated (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Ligand Pharmaceuticals Incorporated.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.79% | $558.59 Million | $1.56 Billion | +16.27pp |
| 2024-12-31 | 19.52% | $183.86 Million | $941.77 Million | +0.80pp |
| 2023-12-31 | 18.72% | $147.35 Million | $787.22 Million | -3.16pp |
| 2022-12-31 | 21.88% | $166.86 Million | $762.67 Million | -2.90pp |
| 2021-12-31 | 24.78% | $321.59 Million | $1.30 Billion | -1.90pp |
| 2020-12-31 | 26.69% | $363.57 Million | $1.36 Billion | -40.09pp |
| 2019-12-31 | 66.78% | $998.32 Million | $1.49 Billion | +63.12pp |
| 2018-12-31 | 3.66% | $46.19 Million | $1.26 Billion | -23.32pp |
| 2017-12-31 | 26.98% | $181.04 Million | $671.02 Million | +6.65pp |
| 2016-12-31 | 20.33% | $122.30 Million | $601.59 Million | +1.08pp |
| 2015-12-31 | 19.25% | $102.79 Million | $533.93 Million | +16.49pp |
| 2014-12-31 | 2.76% | $7.13 Million | $258.03 Million | -1.38pp |
| 2013-12-31 | 4.14% | $4.34 Million | $104.71 Million | +1.49pp |
| 2012-12-31 | 2.65% | $2.77 Million | $104.26 Million | -5.52pp |
| 2011-12-31 | 8.17% | $10.00 Million | $122.35 Million | -17.44pp |
| 2010-12-31 | 25.61% | $19.35 Million | $75.56 Million | -7.11pp |
| 2009-12-31 | 32.72% | $37.20 Million | $113.70 Million | +2.44pp |
| 2008-12-31 | 30.28% | $51.92 Million | $171.45 Million | +20.13pp |
| 2007-12-31 | 10.15% | $17.60 Million | $173.28 Million | +6.03pp |
| 2006-12-31 | 4.12% | $13.45 Million | $326.05 Million | -2.29pp |
| 2005-12-31 | 6.41% | $20.17 Million | $314.62 Million | +0.34pp |
| 2004-12-31 | 6.07% | $20.18 Million | $332.47 Million | -7.21pp |
| 2003-12-31 | 13.28% | $40.00 Million | $301.25 Million | +5.21pp |
| 2002-12-31 | 8.07% | $21.82 Million | $270.61 Million | -6.36pp |
| 2001-12-31 | 14.43% | $16.95 Million | $117.47 Million | +1.70pp |
| 2000-12-31 | 12.73% | $14.44 Million | $113.42 Million | -0.12pp |
| 1999-12-31 | 12.85% | $17.30 Million | $134.60 Million | -- |
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help figh… Read more